NTI
Neurotech International Ltd
Director Trades
| Date | Director | Value |
|---|---|---|
| R. Johnston | $13,275 |
Company News
Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final visit. The child was the 54th patient to take part in the trial, which recruited individuals between the ages of 8 and 17 […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Neurotech International extends NTI164 Rett Syndrome trial to 52 weeks
Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week duration and was approved by the human research ethics committee at Sydney’s Children’s Hospital at Westmead under clinical trial protocol. A total […]
Neurotech International announces strong results from NTI164 PANDAS/PANS trial extension
Neurotech International (ASX: NTI) has announced “highly significant” improvements during the extension phase of a clinical trial into the impact of its lead candidate NTI164 on children with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and paediatric acute-onset neuropsychiatric syndrome (PANS). NTIPANS1 was the first-ever clinical trial to show improvements in PANDAS/PANS patients […]
Neurotech International’s innovative autism spectrum disorder treatment receives 52-week trial extension
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received a 52-week extension to its trial of a potential medicinal cannabis plant extract treatment for children with autism spectrum disorder (ASD). Approval from the human research ethics committee was based on requests from the company’s lead investigator, patients and their caregivers to continue to extend […]
Neurotech International’s NTI164 continues to impress with safe long-term efficacy in paediatric ASD patients
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on the progress of its world-first Phase I/II clinical trial examining the daily use of proprietary broad-spectrum cannabinoid drug therapy NTI164. 11 paediatric patients with autism spectrum disorder (ASD) have now crossed 90 weeks of daily oral therapy with NTI164, which is being […]
Neurotech International receives HREC approval for cerebral palsy treatment trial
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received official approval to commence a trial of its unique NTI164 proprietary drug formulation on paediatric patients with spastic diplegia cerebral palsy (CP). The human research ethics committee (HREC) approval and clinical trial notification scheme clearance by the Therapeutic Goods Administration provides the go-ahead for a […]
Neurotech International poised for autism treatment breakthroughs with NTI164
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has a number of major developments approaching in 2024 after completing a successful 2023. In releasing its December quarterly report, Neurotech highlighted the importance of its investigations into the value proposition in Australia for patients with Autism Spectrum Disorder (ASD) and its world-first trial with its NTI164 […]
Neurotech International completes patient recruitment for pioneering autism spectrum disorder trial
Paediatric neurological disorders specialist Neurotech International (ASX: NTI) has successfully completed patient recruitment for a phase II/III clinical trial assessing potential treatments for children with autism spectrum disorder (ASD). The next phase of the trial will further assess Neurotech’s NTI164 development, a proprietary drug formulation derived from a unique cannabis strain with low tetrahydrocannabinol, or […]
Neurotech International receives approval to extend trial to adult ASD patients
Clinical-stage biopharmaceutical company Neurotech International (ASX: NTI) has been granted approval by the Human Research Ethics Committee (HREC) to extend their current Phase II/III clinical trial in Autism Spectrum Disorder (ASD) patients. The extension allows patients who turn 18 years of age to continue receiving treatment with NTI164 during the extended phase of the trial […]
